Introducing Smart MDI
Take power over T1D with the joint forces of CGM and insulin insights3,4
Combining the power of real time glucose readings with predictive alerts and personalised insulin dosing* to help you stay ahead of your glucose levels3,4.
MiniMedTM 780G with GuardianTM 4 Sensor
Our most advanced insulin pump system with SmartGuard™ automation for self-adjusting basal delivery with autocorrection dosing.
Automated Self-adjusting insulin pump
The MiniMed™ 780G system^ automatically adjusts insulin delivery to help you reach glycaemic targets with less effort and zero calibrations*1,2.
The portfolio of CareLink™ software reports can identify trends, track daily activities and help your care partner to identify patterns and behaviour which may be affecting you.
Education & Training
Whether it is learning the basics of diabetes, counting carbohydrates, or learning how to effectively use your device, our modules are designed to give you the support you need.
You're a Champion through life's challenges, balancing diabetes with determination. Sharing your story inspires fellow Medtronic Champions worldwide. You are strong and we're even stronger together.
You only need to contact us.
For more than 40 years, Medtronic Diabetes has committed to drive innovation, including new insulin delivery solutions that make life easier by reducing the burden of diabetes and deliver strong clinical outcomes.
ALWAYS FOLLOW THE DIRECTIONS FOR USE.
The MiniMed 780G insulin pump is indicated for use by patients age 7-80 years with Type 1 diabetes, whose total daily dose of insulin is 8 units per day or more. The MiniMed 780G system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to provide an automatic adjustment of insulin delivery based on continuous glucose monitoring (CGM) and can suspend the delivery of insulin when the SG value falls below, or is predicted to fall below, predefined threshold values.
The Guardian 4 sensor is intended for use with the Guardian 4 transmitter to monitor glucose levels in persons with diabetes where self-monitoring of blood glucose (SMBG) is indicated. The sensor is designed to replace fingerstick blood glucose (BG)readings for diabetes treatment decisions. The sensor is intended for insertion into persons ages 7 years and older. The sensor is intended for insertion into the back of the upper arm or the upper buttocks in persons ages 7 through 17 years. The sensor is intended for insertion into the back of the upper arm or the abdomen in persons ages 18 years and older.
^Components sold separately
*A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions.
1. Carlson, A.L. et al. Safety and Glycemic Outcomes During the MiniMed Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. DIABETES TECHNOLOGY & THERAPEUTICS. Vol 24, No. 3 (2022) 1-12.
2. Da Silva J, et al. Real-world Performance of the MiniMed™ 780G System: First Report of Outcomes from 4'120 Users. Diabetes Technol Ther. 2021; doi: 10.1089/dia.2021.0203.
3. Abraham SB, et al. Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts. Journal of Diabetes Science and Technology 2021; 15(1):91–97
4. Smith M, et al, E5 , SIPs Improve Time Below Range in MDI Therapy, AMCP Congress 2020